ReviewTherapeutic advances in neurological disorders2021
Advances in dementia with Lewy bodies.
Review in Therapeutic advances in neurological disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- From Sensory Deprivation to Psychosis: Environmental Mechanisms of Delirium in Dementia-An Eight-Year Retrospective Longitudinal Case Report and Narrative Review.Healthcare (Basel, Switzerland) · 2026Article
- Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.Journal of biomedical science · 2026Article
- Resting-State EEG Features of Cognitive Fluctuations Across the Lewy Body Disease Spectrum.Research square · 2026Article
- Article
- The 100 most influential papers on Lewy body dementias: a bibliometric analysis.Annals of medicine and surgery (2012) · 2025Review
- Quantitative electroencephalography in the diagnosis of dementia with Lewy bodies.Clinical neurophysiology practice · 2025Review
- Exosome-rich mesenchymal stem cell secretome improves strength in patients with amyotrophic lateral sclerosis, Kennedy disease, congenital myasthenic syndrome and Lewy body dementia.American journal of stem cells · 2025Article
- Lewy Body Dementia.Continuum (Minneapolis, Minn.) · 2024Review
- SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms.International journal of molecular sciences · 2024Review
- Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.Neurology · 2024Article
- Lewy body dementia: Overcoming barriers and identifying solutions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Alternative Therapies for Non-Motor Symptoms in Parkinson's Disease: A Mini Review.Neuropsychiatric disease and treatment · 2024Review
- CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.Nature communications · 2023Article
- The Future of Precision Medicine in the Cure of Alzheimer's Disease.Biomedicines · 2023Review
- Genetic modifiers of synucleinopathies-lessons from experimental models.Oxford open neuroscience · 2023Review
- Locus coeruleus alterations in dementia with Lewy bodies: A systematic review.Alzheimer's & dementia (New York, N. Y.)Review
- Bálint syndrome in dementia with lewy bodies: A new phenotypic variant with progression implications?Neurology perspectivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity under the broader term
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.